PAVM Stock Risk & Deep Value Analysis
PAVmed Inc
Healthcare • Medical Devices
DVR Score
out of 10
What You Need to Know About PAVM Stock
We analyzed PAVmed Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran PAVM through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
PAVM Risk Analysis & Red Flags
What Could Go Wrong
Despite recent financing, the company's core businesses (EsoGuard, Veris Health) have not yet achieved sufficient revenue scale to offset high operating expenses. Failure to significantly accelerate commercialization and reduce cash burn within the next 12-18 months will necessitate further dilutive financing, significantly impairing shareholder value or leading to solvency issues.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
High
Regulatory
Medium
Red Flags
- ⚠
Extremely low direct PAVmed revenue ($52k Q4 2025) contrasted with high operating expenses ($6.9M/quarter).
- ⚠
Historical struggles in achieving widespread commercialization for EsoGuard.
- ⚠
Significant potential future dilution from the S-3 registration of 9.23M common shares.
- ⚠
Low current ratio (0.17 at Dec 31, 2025) indicating historical poor liquidity before recent financing.
Upcoming Risk Events
- 📅
Failure to achieve significant acceleration in EsoGuard commercialization
- 📅
Delay or rejection of Veris Health FDA 510(k) clearance
- 📅
Further highly dilutive capital raises without commensurate revenue growth
When to Reconsider
- 🚪
Exit if combined EsoGuard and Veris Health revenue growth decelerates significantly (<50% YoY) over two consecutive quarters.
- 🚪
Sell if cash balance falls below $10M without clear, non-dilutive financing in place.
- 🚪
Exit if Veris Health's FDA 510(k) clearance is rejected or indefinitely delayed.
Unlock PAVM Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does PAVmed Inc (PAVM) Do?
Market Cap
$58.53M
Sector
Healthcare
Industry
Medical Devices
Employees
39
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York
Visit PAVmed Inc WebsiteInvestment Thesis
PAVmed is a high-risk, high-reward speculative investment betting on the successful commercialization of EsoGuard for early esophageal cancer screening and the launch of Veris Health's implantable cardiac monitoring technology. Recent substantial financing has provided a critical runway for these initiatives to gain traction. If management can convert this runway into accelerated revenue growth and market share capture in underserved diagnostic and monitoring segments, the stock has multi-bagger potential, albeit from a very low base and with significant dilution risk.
Is PAVM Stock Undervalued?
Unlock the full AI analysis for PAVM
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
PAVM Price Targets & Strategy
12-Month Target
$28.00
Bull Case
$50.00
Bear Case
$5.00
Valuation Basis
Based on a 12x P/S multiple on projected FY2027 revenue of $25M (assuming significant ramp for EsoGuard and Veris contributions) and a partially diluted share count of 10M shares.
Entry Strategy
Dollar-cost average between $8-$12, seeking accumulation near potential support zones, acknowledging high volatility.
Exit Strategy
Take partial profits at $25-$30 range if commercialization milestones are met. Implement a stop-loss order if significant negative news or breakdown below $6 occurs.
Portfolio Allocation
7-15% for aggressive risk tolerance only, given the high-risk, high-reward nature.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is PAVM Financially Healthy?
Valuation
P/E Ratio
145.97
Price/Sales
324.00
Profitability
Gross Margin
-205.63%
Operating Margin
-30797.18%
Net Margin
564.79%
Return on Equity
1.02%
Revenue Growth
-97.63%
EPS
$-17.84
Balance Sheet
Current Ratio
0.17
Quick Ratio
0.15
Debt/Equity
0.33
Other
Beta (Volatility)
0.77
Does PAVM Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable/Expanding
Moat Sources
2 Identified
The moat, primarily derived from regulatory approvals and proprietary technology, has moderate durability. It can withstand competition until a superior, equally accessible, and cost-effective alternative emerges. Continued clinical validation and market adoption are crucial to strengthen it.
Moat Erosion Risks
- •Emergence of new, more efficient, or less costly non-invasive screening technologies for esophageal precancer.
- •Failure to achieve widespread physician and patient adoption, limiting network effects and entrenchment.
- •Strong competitive response from larger, better-funded diagnostic companies with existing sales channels.
PAVM Competitive Moat Analysis
Sign up to see competitive advantages
PAVM Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral. As a small-cap biotech, social media sentiment is likely mixed, with both optimistic retail investors and skeptics, but no broad strong consensus.
Institutional Sentiment
Neutral/Negative. Lack of analyst coverage and explicit institutional ownership data suggests low institutional interest or conviction currently. The recent capital raises, while crucial, often signify a challenging financial position to institutional investors.
Insider Activity (Form 4)
Chairman/CEO Lishan Aklog, M.D. received 350,000 restricted common stock shares on April 2, 2026, vesting May 20, 2029, increasing his beneficial ownership to 5.1% of outstanding shares. This indicates long-term commitment rather than market-based conviction via open-market purchases.
Options Flow
Normal options activity. No specific unusual options activity or put/call ratio skew was indicated in the research data.
Earnings Intelligence
Next Earnings
Estimated late May 2026 (for Q1 2026, though specific date not confirmed).
Surprise Probability
Medium. Given the low revenue base, any significant ramp-up in EsoGuard test volumes or unexpected progress could lead to a 'surprise', but the company has historically faced commercialization challenges.
Historical Earnings Pattern
Highly volatile. Small-cap biotech companies typically experience significant stock price fluctuations around earnings reports, especially with news related to product development, regulatory approvals, or commercialization progress. The market reacts strongly to updates on cash runway and burn.
Key Metrics to Watch
Competitive Position
Top Competitor
Exact Sciences Corp. (EXAS)
Market Share Trend
Gaining, but from a very low base. EsoGuard is targeting a largely underserved market with slow but increasing adoption.
Valuation vs Peers
Difficult to provide direct valuation comparison due to negligible revenue and negative earnings. PAVM trades at an effectively infinite P/E and would command an extremely high P/S if valued on future potential, rather than current sales, significantly above established profitable peers like Exact Sciences (P/S ~6-7x).
Competitive Advantages
- •FDA 510(k) clearance for EsoGuard and EsoCheck, enabling non-endoscopic esophageal precancer screening.
- •Proprietary technology for less invasive diagnostic procedures.
- •Growing real-world data demonstrating EsoGuard's clinical utility (over 12,000 patients).
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive PAVM Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (estimated late May 2026)
- •Lucid Diagnostics $18M common stock offering closure (April 2026)
- •Progress updates on Veris Health FDA 510(k) pathway
Medium-Term (6-18 months)
- •Accelerated adoption rates and increasing test volumes for EsoGuard
- •Successful FDA 510(k) clearance for Veris Health implantable monitor (late 2026)
- •Announcements of new strategic partnerships or VA contract expansions for Lucid Diagnostics
Long-Term (18+ months)
- •Significant market penetration of EsoGuard for routine esophageal cancer screening
- •Full commercialization and widespread adoption of Veris Health platform
- •Expansion into new diagnostic indications or medical device markets
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for PAVM?
- ✓
Significant acceleration in EsoGuard test volumes (e.g., >50% QoQ growth consistently)
- ✓
Positive FDA 510(k) clearance and initial commercial traction for Veris Health.
- ✓
Evidence of improving operating leverage and progress towards cash flow positivity.
Bull Case Analysis
See what could go right with Premium
Competing with PAVM
See how PAVmed Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
PAVmed Inc PAVM | $58.5M | 3.3 | 146.0 | $29,000 | 564.8% | -97.6% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How PAVmed Inc Makes Money
PAVmed Inc. is a medical technology company focused on commercializing innovative devices and diagnostics for unmet clinical needs. Its primary operations are through its majority-owned subsidiary, Lucid Diagnostics, which markets EsoGuard and EsoCheck, non-invasive tests for early detection of esophageal precancer. PAVmed also operates Veris Health, developing an implantable cardiac monitor aimed at cancer patients. The company generates revenue through the sales of these diagnostic tests and anticipated sales of medical devices, targeting healthcare providers, clinics, and government health systems to improve patient outcomes.
Read Full Business Model BreakdownFAQ
What is the DVR Score for PAVmed Inc (PAVM)?
As of April 24, 2026, PAVmed Inc has a DVR Score of 3.3 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of PAVmed Inc?
PAVmed Inc's market capitalization is approximately $58.5M. The company operates in the Healthcare sector within the Medical Devices industry.
What ticker symbol does PAVmed Inc use?
PAVM is the ticker symbol for PAVmed Inc. The company trades on the NCM.
What is the risk level for PAVM stock?
Our analysis rates PAVmed Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of PAVM?
PAVmed Inc currently has a price-to-earnings (P/E) ratio of 146.0. This is above the market average, suggesting the stock may be priced for high growth expectations.
Is PAVmed Inc's revenue growing?
PAVmed Inc has reported revenue growth of -97.6%. Revenue has been declining, which warrants closer examination.
Is PAVM stock profitable?
PAVmed Inc has a profit margin of 564.8%. This indicates strong profitability.
How often is the PAVM DVR analysis updated?
Our AI-powered analysis of PAVmed Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 24, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for PAVM (PAVmed Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.